# A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

> **NCT06847464** · PHASE1 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 48 (actual)

## Conditions studied

- RSV Infection
- Drug Drug Interaction (DDI)

## Interventions

- **DRUG:** EDP-323
- **DRUG:** Itraconazole
- **DRUG:** EDP-323
- **DRUG:** carbamazepine
- **DRUG:** EDP-323
- **DRUG:** Quinidine
- **DRUG:** EDP-323
- **DRUG:** fluconazole

## Key facts

- **NCT ID:** NCT06847464
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-27
- **Primary completion:** 2025-05-24
- **Final completion:** 2025-06-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06847464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06847464, "A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06847464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*